A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00358553
- Lead Sponsor
- Baxter Healthcare Corporation
- Brief Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, and safety of recombinant human insulin. The study will consist of 2 phases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
- Healthy Male Subjects
- Age between 18 and 40 years of age
Exclusion Criteria
- History of Diabetes
- Subjects with clinically significant active disease
- Known allergy to insulin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Profil
🇩🇪Neuss, Germany